| Rivian Automotive [RIVN] - Last Close: $21.62 An analyst upgrade is boosting shares of Rivian. This morning, analysts at Wedbush maintained their "outperform" rating on EV manufacturer, and raised its price target to $30 from $25. Analysts noted their confidence in Rivian's ability to achieve or improve upon its delivery targets. RIVN is up 4.3% on elevated trading volume in today's premarket, My Take: RIVN has been on an incredible run over the past week or so. Shares closed at $13.45 on June 26th, and it's on pace to add to its gains in today's session. Gorilla Technology [GRRR] - Last Close: $2.09 Gorilla Technology just landed a huge government contract. On Thursday evening, the IoT firm said it signed a three-year contract with Egypt's central government that could be worth more than $20 million. Gorilla will help the Egyptian government implement a "Smart Government Security Convergence" solution, according to the press release. It's the largest deal in Gorilla Tech's history, and it puts the company on pace to achieve profitability by the end of 2024. GRRR is one of today's top stocks with a 72.7% gain. My Take: One lucrative government contract can often lead to many more. If GRRR can successfully execute this deal, the company could draw interest from more government buyers. ZyVersa Therapeutics [ZVSA] - Last Close: $0.24 ZyVersa Therapeutics is trending after scoring a pivotal patent. This morning, news broke that the European Patent Office has approved a patent for one of the biopharma firm's key therapeutics. The EPO granted a patent covering ZyVersa's Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. The company says it expects VAR 200 to advance into its next phase of clinical trials in the fourth quarter. ZVSA is up 58.3% on the news. My Take: ZVSA is a long-shot biotech stock, but it could have some upside if it can successfully bring VAR 200 to market. T2 Biosystems [TTOO] - Last Close: $0.083 The Smart Money is taking an interest in T2 Bio. After Thursday's close, regulatory filings revealed that CR Group LP has taken a substantial position in the struggling biotech stock. According to the disclosure, CR Group purchased roughly 48 million shares of TTOO common stock on July 3rd. The firm now controls more than 10% of T2 Bio, and shares are reacting favorably to the news. TTOO is up 18.9% on active trading volume this morning. My Take: TTOO has performed terribly over the past six months, but maybe CR Group can help turn the company around. The fact that the firm spent so much money to acquire shares of this company implies that it sees some value here. GainersBluejay Diagnostics [BJDX] >> +20.6%Enservco [ENSV] >> +13.2%Top Financial [TOP] >> +12.1%Cadiz [CDZI] >> +10.7%DeclinersAbacus Life [ABL] >> (17.3%) Healthcare Triangle [HCTI] >> (12.5%)iMedia Brands [IMBI] >> (16.5%)EdtechX [EDX] >> (16.5%) Azz Inc. [AZZ] ... PM U.S. nonfarm payroll [Jun] ... 8:30a U.S. unemployment rate [Jun] ... 8:30a U.S. hourly wages [Jun] ... 8:30a | 